Page last updated: 2024-08-24

triazoles and epoetin alfa

triazoles has been researched along with epoetin alfa in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chaigneau, L; Demarchi, M; Lorgis, V; Maurina, T; Meaux-Ruault, N; N'guyen, T; Pivot, X; Stein, U; Thiery-Vuillemin, A; Villanueva, C	1
Guinea de Castro, JM; Moreno de Gusmão, B; Oiartzabal, I; Perez-Persona, E	1
Akizawa, T; Bernhardt, T; Berns, JS; Iekushi, K; Krueger, T; Macdougall, IC; Staedtler, G; Taguchi, M	1

Trials

1 trial(s) available for triazoles and epoetin alfa

Article	Year
Long-Term Efficacy and Safety of Molidustat for Anemia in Chronic Kidney Disease: DIALOGUE Extension Studies. American journal of nephrology, 2019, Volume: 49, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Anemia; Darbepoetin alfa; Drug Administration Schedule; Epoetin Alfa; Female; Hematinics; Hemoglobins; Humans; Long-Term Care; Male; Middle Aged; Pyrazoles; Renal Dialysis; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome; Triazoles	2019

Article

Year

Long-Term Efficacy and Safety of Molidustat for Anemia in Chronic Kidney Disease: DIALOGUE Extension Studies.

American journal of nephrology, 2019, Volume: 49, Issue:4

Topics: Adult; Aged; Aged, 80 and over; Anemia; Darbepoetin alfa; Drug Administration Schedule; Epoetin Alfa; Female; Hematinics; Hemoglobins; Humans; Long-Term Care; Male; Middle Aged; Pyrazoles; Renal Dialysis; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome; Triazoles

2019

Other Studies

2 other study(ies) available for triazoles and epoetin alfa

Article	Year
Anticancer therapy in patients with porphyrias: evidence today. Expert opinion on drug safety, 2008, Volume: 7, Issue:2 Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Docetaxel; Epoetin Alfa; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Hematinics; Humans; Letrozole; Middle Aged; Nitriles; Porphyria, Acute Intermittent; Porphyria, Variegate; Recombinant Proteins; Risk Assessment; Taxoids; Triazoles; Uterine Neoplasms	2008
[Transfusional independence in a patient with refractory anemia with excess blasts-2 refractory to 5-azacitidine treated with deferasirox and colony stimulating factors]. Medicina clinica, 2014, Jan-21, Volume: 142, Issue:2 Topics: Aged; Anemia, Refractory, with Excess of Blasts; Azacitidine; Benzoates; Blood Transfusion; Chelation Therapy; Combined Modality Therapy; Deferasirox; Disease Progression; Drug Resistance; Epoetin Alfa; Erythropoietin; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Humans; Iron; Iron Chelating Agents; Leukemia, Myeloid, Acute; Male; Recombinant Proteins; Triazoles	2014

Article

Year

Anticancer therapy in patients with porphyrias: evidence today.

Expert opinion on drug safety, 2008, Volume: 7, Issue:2

Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Docetaxel; Epoetin Alfa; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Hematinics; Humans; Letrozole; Middle Aged; Nitriles; Porphyria, Acute Intermittent; Porphyria, Variegate; Recombinant Proteins; Risk Assessment; Taxoids; Triazoles; Uterine Neoplasms

2008

[Transfusional independence in a patient with refractory anemia with excess blasts-2 refractory to 5-azacitidine treated with deferasirox and colony stimulating factors].

Medicina clinica, 2014, Jan-21, Volume: 142, Issue:2

Topics: Aged; Anemia, Refractory, with Excess of Blasts; Azacitidine; Benzoates; Blood Transfusion; Chelation Therapy; Combined Modality Therapy; Deferasirox; Disease Progression; Drug Resistance; Epoetin Alfa; Erythropoietin; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Humans; Iron; Iron Chelating Agents; Leukemia, Myeloid, Acute; Male; Recombinant Proteins; Triazoles

2014